Buscar
NewAmsterdam Pharma Company NV
NAMSAñadir a la lista de seguimiento
33.890USD
+0.020+0.06%
Cierre 06/30, 16:00（ET）Cotizaciones retrasadas 15 min
3.96BCap. mercado
PérdidaP/E TTM
Más Datos de NewAmsterdam Pharma Company NV Compañía
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.
Información de NewAmsterdam Pharma Company NV
Símbolo de cotizaciónNAMS
Nombre de la empresaNewAmsterdam Pharma Company NV
Fecha de salida a bolsaNov 23, 2022
Director ejecutivoDavidson (Michael Harvey)
Número de empleados68
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 23
DirecciónGooimeer 2-35
CiudadNAARDEN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísNetherlands
Código postal1411 DC
Teléfono31352062971
Sitio Webhttps://ir.newamsterdampharma.com/
Símbolo de cotizaciónNAMS
Fecha de salida a bolsaNov 23, 2022
Director ejecutivoDavidson (Michael Harvey)
Ejecutivos de NewAmsterdam Pharma Company NV
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
2.32K
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.32K
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
2.32K
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
Ms. Juliette Audet
Ms. Juliette Audet
Chief Business Officer
Chief Business Officer
--
--
Dr. Louis Lange, M.D., Ph.D.
Dr. Louis Lange, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Nicholas Downing, M.D.
Dr. Nicholas Downing, M.D.
Director
Director
--
--
Ms. Janneke Van Der Kamp
Ms. Janneke Van Der Kamp
Temporary Non-Executive Director
Temporary Non-Executive Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John W. Smither
Mr. John W. Smither
Temporary Non-Executive Independent Director
Temporary Non-Executive Independent Director
2.32K
--
Mr. William H. (Will) Lewis, J.D.
Mr. William H. (Will) Lewis, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
2.32K
--
Mr. Mark C. Mckenna
Mr. Mark C. Mckenna
Independent Director
Independent Director
2.32K
--
Dr. James N. Topper, M.D., Ph.D.
Dr. James N. Topper, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Michael Harvey Davidson, M.D.
Dr. Michael Harvey Davidson, M.D.
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Dr. John Kastelein
Dr. John Kastelein
Chief Scientific Officer, Non-Executive Director
Chief Scientific Officer, Non-Executive Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de NewAmsterdam Pharma Company NV?
Los cinco principales accionistas de NewAmsterdam Pharma Company NV son: Mr. John W. Smither
¿Cuántas instituciones poseen acciones de NewAmsterdam Pharma Company NV (NAMS)?
A fecha de 2026Q1, 366 instituciones poseen acciones de NewAmsterdam Pharma Company NV, con un valor de mercado combinado de aproximadamente 128.70M, lo que representa el 110.09% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 2432976.00.